| Late toxicity after adjuvant conventional radiation versus image-guided intensity-modulated radiotherapy for cervical cancer (PARCER): a randomized controlled trial S Chopra, S Gupta, S Kannan, T Dora, R Engineer, A Mangaj, ... Journal of Clinical Oncology 39 (33), 3682-3692, 2021 | 141 | 2021 |
| Concurrent chemoradiation and brachytherapy alone or in combination with nelfinavir in locally advanced cervical cancer (NELCER): study protocol for a phase III trial S Chopra, JS Goda, P Mittal, J Mulani, S Pant, V Pai, S Kannan, ... BMJ open 12 (4), e055765, 2022 | 9 | 2022 |
| Months and Severity Score (MOSES) in a Phase III trial (PARCER): A new comprehensive method for reporting adverse events in oncology clinical trials N Ranjan, S Chopra, A Mangaj, P Rane, M Charnalia, S Kannan, T Dora, ... EClinicalMedicine 47, 2022 | 8 | 2022 |
| Late toxicity within a Phase III clinical trial of IG-IMRT in cervix cancer (PARCER): Reanalysis with time weighted adverse event reporting (MOSES) C Supriya, R Nilesh, C Mayuri, K Sadhana, E Reena, D Tapas, G Lavanya, ... Radiotherapy and Oncology 177, 16-20, 2022 | 5 | 2022 |
| Patterns of relapse after adjuvant chemoradiation for cervical cancer in a phase 3 clinical trial (PARCER): An evaluation of updated NRG oncology/RTOG target delineation guidelines P Mittal, S Chopra, M Charnalia, T Dora, R Engineer, J Mulani, L Scaria, ... International Journal of Radiation Oncology* Biology* Physics 113 (2), 369-378, 2022 | 3 | 2022 |
| RECIST 1.1 versus clinico-radiological response assessment for locally advanced cervical cancer: implications on interpreting survival outcomes of future trials M Charnalia, S Chopra, J Mulani, P Popat, S Rath, M Thomeer, P Mittal, ... International Journal of Gynecological Cancer 34 (6), 817-823, 2024 | 2 | 2024 |
| Defining Optimal Nodal Dose for Stage IIIC Cervical Cancer: An Institutional Audit of Patients Treated with Simultaneous Integrated Nodal Boost P Mittal, S Karmakar, A Raut, J Mulani, M Charnalia, A Gupta, J Jain, ... Indian Journal of Gynecologic Oncology 22 (4), 160, 2024 | | 2024 |
| 2412: DVH-AUC predictors of incidence & prevalence of late GI toxicity: Secondary analysis of PARCER trial J Jain, J Kamalnath, A Gupta, N Ranjan, M Charnalia, P Mittal, S Chopra Radiotherapy and Oncology 194, S1079-S1082, 2024 | | 2024 |
| 2293: Acute gastrointestinal toxicity of concurrent chemoradiation in cervix cancer: EMBRACE-II findings MS Charnalia, K Tanderup, R Pötter, S Chopra, M Pelizzola, ... Radiotherapy and Oncology 194, S1071-S1074, 2024 | | 2024 |
| EP050/# 898 Does higher nodal dose impact nodal control in cervical cancer: an analysis of patients treated with nodal simultaneous integrated boost for cervical cancer S Chopra, S Karmakar, P Mittal, A Raut, J Mulani, M Charnalia, A Gupta, ... International Journal of Gynecological Cancer 33, A100-A101, 2023 | | 2023 |
| OC-0606 Severity and time-weighted gastrointestinal morbidity in cervix cancer: EMBRACE analysis with MOSES M Charnalia, N Ranjan, S Spampinato, R Pötter, IM Jürgenliemk-Schulz, ... Radiotherapy and Oncology 182, S489-S490, 2023 | | 2023 |
| PO-1341 RECIST 1.1 in cervix cancer radiation and drug trials: Is there a difference in measured outcomes? S Chopra, M Charnalia, J Mulani, P Popat, S Rath, L Gurram, P Mittal, ... Radiotherapy and Oncology 170, S1136-S1137, 2022 | | 2022 |
| OC-0763 Time and severity weighted late toxicity (MOSES): Reanalysis of a phase III IG-IMRT trial (PARCER) S Chopra, N Ranjan, M Charnalia, S Kannan, R Engineer, T Dora, ... Radiotherapy and Oncology 170, S679-S680, 2022 | | 2022 |
